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Abstract Diadenosine polyphosphates present at the cytosol
can be transported to secretory granules allowing their
exocytotic release. Extracellularly, they can act through specific
metabotropic or ionotropic receptors, or as analogues of P2X
and P2Y nucleotide receptors. The specific ionotropic receptor
P4 is present in synaptic terminals, and modulated by protein
kinases (PK) A and C and protein phosphatases. Activation of
PKA or PKC, directly or through membrane receptors, results in
a decrease of affinity or in reduction of the Ca2+ transient
respectively. Adenosine and ATP, both products of the extra-
cellular destruction of diadenosine polyphosphates, acting
through A1 or P2Y receptors respectively, are important
physiological modulators at the P4 receptor.
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1. Diadenosine polyphosphates: intracellular roles
K,g-adenine dinucleotides have emerged as extracellular sig-
nalling molecules together with adenosine and ATP in neural
and non-neural tissues. Adenine dinucleotides, also termed
diadenosine polyphosphates, are made up of two adenosine
moieties bridged by a phosphate chain whose length varies
between three and six phosphates. It is generally accepted
that some aminoacyl-tRNA synthetases and enzymes with ad-
enylyl reaction intermediates produce these compounds as
secondary products [1^3].
Diadenosine polyphosphates are present in prokaryotic and
eukaryotic cells, their levels, which are below the WM range,
increase to WM levels after oxidative or heat shock treatment
[1,4,5]. In eukaryotic cells, their concentration also depends
on the cell cycle and Ap4A can activate DNA replication and
DNA repair [6,7].
In cell cytoplasm, diadenosine polyphosphates are able to
regulate enzymes, ion channels and transporters. They behave
as enzyme inhibitors involved in the nucleotide phosphate
transfer mediated by adenosine kinase and adenylate kinase,
as they are transition state analogues of these enzymes [8,9].
Nevertheless, they behave as activators of the cytosolic 5P-
nucleotidase [10]. Plasma membrane proteins can be modu-
lated on the intracellular side by diadenosine polyphosphates.
This e¡ect has been demonstrated in the KATP channel
present in cardiac cells, where they mimic the e¡ect of ATP
[11]. In addition, in pancreatic L-cells, an increase in the ex-
tracellular glucose levels produces an enhancement of up to 40
times of Ap3A and Ap4A, reaching intracellular concentra-
tions of 11.2 WM an 13.6 WM respectively, activating the
KATP channel involved in insulin secretion [12]. Moreover,
ATP as well as Ap4A positively modulate the nucleoside
transporter, which is a crucial step in the recovery of extra-
cellular adenosine, on the intracellular side.
Cytosolic hydrolases and phosphorylases, speci¢c for the
phosphate chain length, cleave adenine dinucleotides to
form adenine mononucleotides in both pro- and eukaryotic
cells [13,14]. One of these enzymes, diadenosine triphosphate
hydrolase (Ap3A hydrolase), is the fragile histidine triad pro-
tein (FHIT) which is a tumor suppressor [15].
2. Extracellular roles of diadenosine polyphosphates
2.1. Presence and release
Diadenosine polyphosphates are stored in the secretory
granules, where the presence of adenine mononucleotides
has also been described. Platelets contain signi¢cant amounts
of Ap3A, Ap4A, Ap5A and Ap6A together with ADP and
serotonin in their dense granules [16,17]. Chroma⁄n cells
from adrenal medulla contain Ap4A, Ap5A, and Ap6A ac-
companying ATP and catecholamines [18,19]. In the choliner-
gic model of Torpedo the dinucleotides present in synaptic
vesicles are Ap4A and Ap5A together with acetylcholine and
ATP [20].
The transport of adenine dinucleotides and mononucleo-
tides is carried out by the same vesicular transporter, which
shows little selectivity, but appears to be highly modulated by
the intracellular levels of the substrates, in a kinetic behavior
known as mnemonic [21]. In this model, changes in the cyto-
solic concentration of dinucleotides induce slow conforma-
tional transitions between di¡erent states of the transporter,
which results in drastic variations in transport capacity.
The induced release of adenine dinucleotides from secretory
granules maintains the same proportionality as the granular
content with respect to mononucleotides and aminergic or
cholinergic compounds. Secretion from neural tissues, synap-
tic terminals and chroma⁄n cells requires the presence of
extracellular Ca2, and equivalent amounts of Ap4A, Ap5A
and Ap6A are released [19,22]. Diadenosine polyphosphates,
Ap4A and Ap5A, have been identi¢ed and quanti¢ed by
means of in vivo release experiments using the push-pull tech-
nique in the caudate putamen area of conscious rats after
amphetamine stimulation. The stability of Ap4A and Ap5A
was better than ATP, since only AMP and adenosine were
measured by HPLC together with the dinucleotides [23].
As a result of cellular release the dinucleotide concentration
in the vicinity of the secretory event has been calculated to be
around 25 WM for chroma⁄n cells, these levels signi¢cantly
decreased by dilution when reaching more distant areas [19].
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Concentrations of Ap4A and Ap5A close to 60 nM can be
detected from brain perfusion samples after strong stimula-
tion. These are below 2 nM in non-stimulated brain perfusates
[23]. These data need to be taken into account when studying
speci¢c receptors and physiological actions.
2.2. Receptors
Due to the close structural analogy between diadenosine
polyphosphates and ATP it is necessary to be aware of the
di⁄culties in clearly identifying their speci¢c physiological re-
ceptors and di¡erentiate them from pharmacological actions
on other nucleotide receptors [24]. First approaches to the
adenine dinucleotide receptors were performed by means of
ligand binding studies [25,26]. Several authors described the
existence of binding sites for [3H]Ap4A in bladder, cardiac
cells, chroma⁄n cells, liver and in mouse and rat brain.
Scatchard analyses in most of the cases are not linear plots,
as occurs in rat brain synaptosomes. In this neural model,
combining Scatchard analysis and competition studies, up to
three di¡erent binding sites can be found. One is a very highly
speci¢c binding site (Kd in the pM range), the second is a
highly speci¢c binding site (Kd in the nM range) and the third
is in the WM range.
Autoradiographic studies performed in rat brain with
[3H]Ap4A showed a widespread but heterogeneous distribu-
tion. Cerebellar granular layer, superior olive, VIIth cranial
nerve and some areas in the olfactory bulb were densely
marked [27].
ApnA have proven to be agonists of some nucleotide recep-
tors including metabotropic, P2Y, and ionotropic, P2X.
Among the best known examples are their actions on P2X1
from vas deferens, and the former P2U (now P2Y2) cloned
from human lung tissue [28^30]. Moreover, actions on allo-
steric sites di¡erent from that of ATP have been described on
the homomeric P2X2 expressed in oocytes where Ap5A poten-
tiates the entry of cations at low nM concentrations [31]. This
feature is not only restricted to ionotropic P2X receptors since
the P2Y receptor present in cerebellar astrocytes is also po-
tentiated by Ap5A, e¡ect which lasts for up to 6 h [32].
Receptors only stimulated by diadenosine polyphosphates
have been described in mouse, rat and guinea pig synapto-
somes, and are termed dinucleotide receptors or P4 receptors
[33^35]. This presynaptic receptor is coupled to Ca2 entry by
a mechanism which is voltage independent, nevertheless, the
initial Ca2 entry depolarizes the terminal permitting the
opening of voltage dependent Ca2 channels (VDCC) sensi-
tive to g-conotoxin G-VI-A, indicating the participation of an
N-type Ca2 channel [33]. The dinucleotide receptor present
in mouse brain appears to be coupled to the L-type VDCC
since it is blocked with verapamil [34].
From a pharmacological point of view not all adenine di-
nucleotides present the same maximal e¡ect in rat midbrain
synaptosomes. The most e¡ective is diadenosine pentaphos-
phate, followed by diadenosine tetraphosphate, which is a
partial agonist, diadenosine triphosphate having almost no
e¡ect. Their EC50 values were all similar at around 50 WM
(Fig. 1A). It is noteworthy that dinucleotide receptors present
in rat midbrain are pharmacologically di¡erent from those
present in guinea pig [33,35]. Dinucleotide receptors present
in both cerebellum and in diencephalon of guinea pig induce
Ca2 entry to synaptic terminals similar to that described for
rat midbrain; nevertheless, while in rat Ap5A is the most
e¡ective dinucleotide, in guinea pig the even dinucleotides
(Ap4A and Ap6A) are more e¡ective than Ap3A and Ap5A.
This probably indicates the existence of di¡erent subtypes of
dinucleotide receptors (Fig. 1B). This is also supported by the
receptor present in mouse where Ap4A elicits bigger Ca2
transients than in rat and guinea pig but with an EC50 that
is also higher (214 WM) [34].
The dinucleotide receptor is not sensitive to P2 antagonists
such as suramin, DIDS (4,4P-diisothiocyanostilbene-2,2P-disul-
fonic acid) and PPADS (pyridoxalphoshate-6-azophenyl-2P,4P-
disulfonic acid). A new series of diadenosine polyphosphates
derivatives, the diinosine polyphosphates (IpnI), behave as
good antagonists of the dinucleotide receptor [36]. These com-
pounds are synthesized by enzymatic deamination of the cor-
responding diadenosine polyphosphates [37]. Ip3I and Ip4I
were antagonists at the WM range but diinosine pentaphos-
phate (Ip5I) with an IC50 value in the nM range was an ex-
cellent antagonist of the midbrain dinucleotide receptor. This
is especially important because antagonists for nucleotide re-
ceptors currently available are poorly speci¢c.
Protein kinases and phosphatases modulate the dinucleotide
receptor present in rat brain [38]. Presynaptic neurotransmit-
ter receptors coupled to stimulation of protein kinases (PK) A
and C reduce the Ca2 transients elicited by 100 WM Ap5A.
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Fig. 1. Heterogeneity of dinucleotide receptors based on the intrasy-
naptosomal Ca2 response curves induced by di¡erent structural
analogues. A: Pharmacology of the dinucleotide receptor present in
rat midbrain synaptic terminals. The best agonist of this receptor is
Ap5A, Ip4I being an antagonist. B: Pharmacology of the dinucleo-
tide receptor present in cerebellar guinea pig synaptic terminals. The
best full agonist was Ap4A whereas in terms of a⁄nity the best was
Ip4I.
M.T. Miras-Portugal et al./FEBS Letters 430 (1998) 78^82 79
Activators of PKA, such as forskolin (which stimulates ad-
enylate cyclase), inhibited the response elicited by Ap5A.
PDBu, which activates PKC, also inhibited the Ca2 transi-
ents elicited by Ap5A. Inhibitors of PKA and PKC, such as
the PKA inhibitory peptide or staurosporine respectively, fa-
vored the Ca2 transients induced by Ap5A (Fig. 2).
The e¡ect of protein kinases is reversed by protein phos-
phatases which allow a better functioning of the dinucleotide
receptor when stimulated by 100 WM Ap5A. This has been
demonstrated by blocking the activity of phosphatases with
okadaic acid (general inhibitor of PPases), microcystin (inhib-
itor of PP2A) and cyclosporin (an inhibitor of calcineurin).
The existence of a battery of ecto-nucleotidases in the syn-
aptic cleft permits the cleavage of diadenosine polyphosphates
and ATP to adenosine (see below) [39]. To see whether ad-
enosine and ATP may produce any change in diadenosine
polyphosphate responses, alkaline phosphatase was added to
the synaptosomal preparation transforming the ATP present
at the extracellular space into adenosine (Fig. 3). Disappear-
ance of ATP and appearance of adenosine produced a dual
e¡ect on the Ap5A dose-response curve. Firstly, the sigmoidal
dose-response curve for Ap5A was transformed in a biphasic
curve, which presented a component in the nanomolar range
plus another in the micromolar range. Secondly, the maximal
e¡ect of the WM step was higher than in control. In the pres-
ence of alkaline phosphatase, the nM component of the dose-
response curve returned to WM values when the adenosine A1
receptor was blocked with the speci¢c antagonist DPCPX
[40]. This indicates that adenosine through an A1 receptor
(negatively coupled to adenylate cyclase and reducing the
PKA activity) permits the dinucleotide receptor to reach a
higher a⁄nity state than in the absence of the nucleoside.
The change in the maximal e¡ect was not due to adenosine
but to ATP degradation, since in the absence of alkaline
phosphatase but in the presence of the P2 antagonist PPADS,
the maximal response was increased to the same extent as with
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Fig. 2. Dinucleotide receptor modulation by intracellular signalling. Schematic diagram of the dinucleotide receptor modulation by stimulation
of second messenger systems coupled to membrane receptors in rat midbrain synaptic terminals. Activation of protein kinases A and C severely
diminishes the a⁄nity and the maximal e¡ect of the receptor respectively. The action of di¡erent e¡ectors which produce changes in the a⁄nity
and maximal e¡ects on the dinucleotide receptor. The adenosine e¡ect is mediated in this model through an A1 receptor which inhibits adenyl-
ate cyclase (AC), while ATP stimulates a P2Y receptor positively coupling to phospholipase C (PLC). PKA-IP and PKC-IP are respectively
protein kinases A and C inhibitory peptides. Staurosp. corresponds to staurosporine, PDBu to phorbol 12,13-dibutyrate and DiBucAMP is di-
butyryl-cAMP.
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the enzyme [41]. A P2Y type receptor, coupled to PLC and
activating PKC, would be responsible for a reduction in the
activity of the dinucleotide receptor. These results correlate
well with the action of protein kinases and phosphatases.
Stimulation of rat brain synaptic terminals releases diade-
nosine polyphosphates as well as ATP. The amount of ATP is
approximately 25 times higher than that of dinucleotides [22].
In this initial situation, the dinucleotide receptor would be
sensitive to Ap5A with an EC50 in the WM range and a max-
imal e¡ect of about 30 nM, because ATP activates a P2 re-
ceptor. As soon as ecto-nucleotidases start cleaving ATP and
adenosine appears, this nucleoside acting through the adeno-
sine A1 receptor produces a change in the dinucleotide recep-
tor that makes it more sensitive to Ap5A, the EC50 thus being
in the nM range.
2.3. Ectoenzymatic degradation of dinucleotides
The existence of ecto-enzymes able to hydrolyze diadeno-
sine polyphosphates with high a⁄nity has been reported in
endothelial cells from blood vessels, cultured chroma⁄n cells
and plasma membranes from Torpedo synaptic terminals [42^
45]. Their Km values for ApnA (n=3^5) are around 0.5^5 WM.
All these enzymes hydrolyse the ApnA in an asymmetric way,
producing AMP and the corresponding Apn31 nucleotide,
these compounds being substrates of a cascade of ectonucleo-
tidase activities, including ecto-ATPase (or apyrase) and 5P-
nucleotidase, producing adenosine as ¢nal product [39].
Di¡erences between the e¡ect of ions on diadenosine poly-
phosphate hydrolases present in neural tissues and endothelial
cells have been described, suggesting the presence of distinct
forms of the enzyme in these two types of tissue. The enzymes
of neural origin were stimulated by Ca2, Mg2 and Mn2 in
a similar way, whereas vascular endothelial enzymes were in-
hibited by Ca2, Mn2 being a much more potent activator of
this activity than Mg2 [43,45,46].
Finally, it is worth noting that the existence of high a⁄nity
ecto-enzymes able to hydrolyze diadenosine polyphosphates
and terminate their actions through purinergic receptors con-
tributes to con¢rming the role of these dinucleotides as ex-
tracellular messengers (Figs. 1^3).
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